Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 1/2017

18.02.2016 | Original Article

Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype

verfasst von: Dalia Salem, Sherin Abd El-Aziz, Nadia El-Menshawy, Tarek Abouzeid, Mohamed Ebrahim

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Mutation in IDH1 gene was suggested to be associated with bad prognosis in cytogenetically normal AML (CN-AML). However, there are conflicting data about its prognostic impact. Besides, its prevalence and prognostic significance in Egyptian patients still not fully stated. We aimed to assess the prevalence of IDH1R132 mutation in Egyptian CN-AML patients, its correlation with FAB subtypes, and clinical outcome of those patients. Sequencing of amplified IDH1 gene exon four from 50 patients was performed to detect codon R132 point mutation. High prevalence of IDH1 mutation was detected in our patients (9/50, 18 %). Mutated IDH1R132 was associated with older age and higher platelets count (p = 0.04 and 0.01 respectively). The most common FAB subtype associated with mutated IDH1R132 was AML-M2 followed by M4. In multivariate analysis, IDH1R132 mutation was found as independent prognostic variable. It was significantly associated with lower CR and shorter OS (p = 0.06 and 0.009 respectively).
Literatur
1.
Zurück zum Zitat Ferrara F, Palmieri S, Leoni F (2008) Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol 66(3):181–193CrossRefPubMed Ferrara F, Palmieri S, Leoni F (2008) Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol 66(3):181–193CrossRefPubMed
2.
Zurück zum Zitat Gaidzik V, Dohner K (2008) Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 35(4):346–355CrossRefPubMed Gaidzik V, Dohner K (2008) Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 35(4):346–355CrossRefPubMed
3.
Zurück zum Zitat Scholl S, Fricke HJ, Sayer HG, Hoffken K (2009) Clinical implications of molecular genetic aberrations in acute myeloid leukemia. J Cancer Res Clin Oncol 135(4):491–505CrossRefPubMed Scholl S, Fricke HJ, Sayer HG, Hoffken K (2009) Clinical implications of molecular genetic aberrations in acute myeloid leukemia. J Cancer Res Clin Oncol 135(4):491–505CrossRefPubMed
4.
Zurück zum Zitat Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352(3):254–266CrossRefPubMed Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352(3):254–266CrossRefPubMed
5.
Zurück zum Zitat Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobiset K et al (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100(13):4372–4380CrossRefPubMed Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobiset K et al (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100(13):4372–4380CrossRefPubMed
6.
Zurück zum Zitat Frohling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S et al (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22(4):624–633CrossRefPubMed Frohling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S et al (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22(4):624–633CrossRefPubMed
7.
Zurück zum Zitat Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A et al (2009) Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 113(19):4505–4511CrossRefPubMed Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A et al (2009) Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 113(19):4505–4511CrossRefPubMed
8.
Zurück zum Zitat Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361(11):1058–1066CrossRefPubMedPubMedCentral Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361(11):1058–1066CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6):597–602CrossRefPubMed Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6):597–602CrossRefPubMed
10.
Zurück zum Zitat Ducray F, Marie Y, Sanson M (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(21):2248–2249 (author reply 2249) CrossRefPubMed Ducray F, Marie Y, Sanson M (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(21):2248–2249 (author reply 2249) CrossRefPubMed
12.
Zurück zum Zitat Wagner K, Damm F, Gohring G, Görlich K, Heuser M, Schäfer I et al (2010) Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 28(14):2356–2364CrossRefPubMed Wagner K, Damm F, Gohring G, Görlich K, Heuser M, Schäfer I et al (2010) Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 28(14):2356–2364CrossRefPubMed
13.
Zurück zum Zitat Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W et al (2010) Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 115(14):2749–2754CrossRefPubMed Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W et al (2010) Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 115(14):2749–2754CrossRefPubMed
14.
Zurück zum Zitat Tharapel AT (1997) ISCN-1995—guidelines for in situ-hybridization nomenclature. Cytogenet Cell Genet 77(1–2):37-37 Tharapel AT (1997) ISCN-1995—guidelines for in situ-hybridization nomenclature. Cytogenet Cell Genet 77(1–2):37-37
15.
Zurück zum Zitat Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27(25):4150–4154CrossRefPubMed Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27(25):4150–4154CrossRefPubMed
16.
Zurück zum Zitat Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD (2007) Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 109(2):431–448CrossRefPubMedPubMedCentral Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD (2007) Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 109(2):431–448CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Dohner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 115(3):453–474CrossRefPubMed Dohner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 115(3):453–474CrossRefPubMed
18.
Zurück zum Zitat Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812CrossRefPubMedPubMedCentral Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ et al (2011) Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol 135(1):35–45CrossRefPubMed Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ et al (2011) Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol 135(1):35–45CrossRefPubMed
20.
Zurück zum Zitat Fernandez-Mercado M, Yip BH, Pellagatti A, Davies C, Larrayoz MJ, Kondo T et al (2012) Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics. PLoS ONE 7(8):e42334CrossRefPubMedPubMedCentral Fernandez-Mercado M, Yip BH, Pellagatti A, Davies C, Larrayoz MJ, Kondo T et al (2012) Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics. PLoS ONE 7(8):e42334CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Elsayed GM, Nassar HR, Zaher A, Elnoshokaty EH, Moneer MM (2014) Prognostic value of IDH1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients. J Egypt Natl Canc Inst 26(1):43–49CrossRefPubMed Elsayed GM, Nassar HR, Zaher A, Elnoshokaty EH, Moneer MM (2014) Prognostic value of IDH1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients. J Egypt Natl Canc Inst 26(1):43–49CrossRefPubMed
22.
Zurück zum Zitat Guan L, Gao L, Wang L, Li M, Yin Y, Yu L et al (2013) The frequency and clinical significance of IDH1 mutations in chinese acute myeloid leukemia patients. PLoS ONE 8(12):e83334CrossRefPubMedPubMedCentral Guan L, Gao L, Wang L, Li M, Yin Y, Yu L et al (2013) The frequency and clinical significance of IDH1 mutations in chinese acute myeloid leukemia patients. PLoS ONE 8(12):e83334CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI et al (2009) Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125(2):353–355CrossRefPubMed Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI et al (2009) Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125(2):353–355CrossRefPubMed
24.
Zurück zum Zitat Zhang Y, Wei H, Wang M, Huai L, Mi Y, Zhang Y et al (2011) Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients. Leuk Res 35(10):1301–1306CrossRefPubMed Zhang Y, Wei H, Wang M, Huai L, Mi Y, Zhang Y et al (2011) Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients. Leuk Res 35(10):1301–1306CrossRefPubMed
25.
Zurück zum Zitat Neubauer A, Maharry K, Mrozek K, Thiede C, Marcucci G, Paschka P et al (2008) Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol 26(28):4603–4609CrossRefPubMedPubMedCentral Neubauer A, Maharry K, Mrozek K, Thiede C, Marcucci G, Paschka P et al (2008) Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol 26(28):4603–4609CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366(12):1079–1089CrossRefPubMedPubMedCentral Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366(12):1079–1089CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L et al (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28(22):3636–3643CrossRefPubMed Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L et al (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28(22):3636–3643CrossRefPubMed
28.
Zurück zum Zitat Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T et al (2012) Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer 118(10):2665–2673CrossRefPubMed Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T et al (2012) Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer 118(10):2665–2673CrossRefPubMed
29.
Zurück zum Zitat Koszarska M, Bors A, Feczko A, Meggyesi N, Batai A, Csomor J et al (2013) Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia. Leuk Lymphoma 54(5):1028–1035CrossRefPubMed Koszarska M, Bors A, Feczko A, Meggyesi N, Batai A, Csomor J et al (2013) Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia. Leuk Lymphoma 54(5):1028–1035CrossRefPubMed
Metadaten
Titel
Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype
verfasst von
Dalia Salem
Sherin Abd El-Aziz
Nadia El-Menshawy
Tarek Abouzeid
Mohamed Ebrahim
Publikationsdatum
18.02.2016
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2017
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-016-0649-z

Weitere Artikel der Ausgabe 1/2017

Indian Journal of Hematology and Blood Transfusion 1/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.